- Home
- MHH vs FLNA Comparison
MHH vs FLNA Comparison
Compare MHH & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHH | FLNA |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.3M | 61.8M |
| IPO Year | 2008 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MHH | FLNA |
|---|---|---|
| Price | $6.79 | $0.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | ★ $12.75 | $6.50 |
| AVG Volume (30 Days) | 6.1K | ★ 610.2K |
| Earning Date | 10-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,371,000.00 | $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.86 | N/A |
| P/E Ratio | $634.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $0.62 |
| 52 Week High | $8.37 | $2.03 |
Technical Indicators
Market Signals| Indicator | MHH | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 32.21 |
| Support Level | $6.24 | N/A |
| Resistance Level | $6.80 | $1.05 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 20.20 | 3.79 |
Price Performance
Historical ComparisonAbout MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.